Arbor Biotechnologies Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in Rare Liver Diseases

Arbor Biotechnologies announced that it has entered into an agreement with Acuitas Therapeutics. As part of the agreement, the companies will combine the optimized delivery of Acuitas’ highly validated lipid nanoparticles technology with Arbor’s CRISPR gene editing technology designed for use in vivo in patients with rare liver diseases.